Hemorrhagic Cystitis Clinical Trial
The purpose of this study is to evaluate the safety and efficacy using placenta derived decidual stromal cell therapy for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. It is hypothesized that the decidual stromal cell therapy is safe to infuse and that they have a positive clinical effect.
Patients with grade 2-4 hemorrhagic cystitis will receive decidual stromal cell therapy at approximately 1-2x10^6 cells/kg once or at weekly intervals dependent on clinical effect. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03129126 -
The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
|
Phase 2 | |
| Recruiting |
NCT04696666 -
Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis
|
N/A | |
| Recruiting |
NCT05348239 -
Chlorophyllin Tablets for Urinary Bleeding Following Radiation Therapy for Cancers of Pelvic Organs
|
Phase 2 | |
| Recruiting |
NCT02174536 -
A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis
|
Phase 2 | |
| Terminated |
NCT04390113 -
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
|
Phase 3 | |
| Not yet recruiting |
NCT06241274 -
Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT
|
N/A | |
| Not yet recruiting |
NCT06198517 -
Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
|
N/A | |
| Recruiting |
NCT05726786 -
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
|
Phase 3 |